Heron Therapeutics, Inc. (HRTX)
0.3182
+0.01
(+1.69%)
USD |
NASDAQ |
Sep 03, 10:18
Heron Therapeutics Research and Development Expense (TTM) : 12.00M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.00M |
| March 31, 2026 | 12.04M |
| December 31, 2025 | 11.93M |
| September 30, 2025 | 11.36M |
| June 30, 2025 | 12.66M |
| March 31, 2025 | 14.35M |
| December 31, 2024 | 16.68M |
| September 30, 2024 | 24.46M |
| June 30, 2024 | 33.55M |
| March 31, 2024 | 46.69M |
| December 31, 2023 | 55.90M |
| September 30, 2023 | 56.00M |
| June 30, 2023 | 67.99M |
| March 31, 2023 | 79.25M |
| December 31, 2022 | 107.51M |
| September 30, 2022 | 125.33M |
| June 30, 2022 | 128.38M |
| March 31, 2022 | 134.78M |
| December 31, 2021 | 130.82M |
| September 30, 2021 | 146.40M |
| June 30, 2021 | 166.98M |
| March 31, 2021 | 175.76M |
| December 31, 2020 | 174.53M |
| September 30, 2020 | 178.36M |
| June 30, 2020 | 163.88M |
| Date | Value |
|---|---|
| March 31, 2020 | 161.30M |
| December 31, 2019 | 167.38M |
| September 30, 2019 | 159.00M |
| June 30, 2019 | 154.71M |
| March 31, 2019 | 143.44M |
| December 31, 2018 | 140.03M |
| September 30, 2018 | 148.00M |
| June 30, 2018 | 146.22M |
| March 31, 2018 | 144.06M |
| December 31, 2017 | 137.08M |
| September 30, 2017 | 118.73M |
| June 30, 2017 | 115.63M |
| March 31, 2017 | 114.92M |
| December 31, 2016 | 98.42M |
| September 30, 2016 | 85.18M |
| June 30, 2016 | 73.88M |
| March 31, 2016 | 62.77M |
| December 31, 2015 | 61.18M |
| September 30, 2015 | 59.12M |
| June 30, 2015 | 59.60M |
| March 31, 2015 | 57.86M |
| December 31, 2014 | 55.12M |
| September 30, 2014 | 50.52M |
| June 30, 2014 | 41.68M |
| March 31, 2014 | 37.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Praxis Precision Medicines, Inc. | 290.71M |
| Tonix Pharmaceuticals Holding Corp. | 63.86M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |